Deborah Waterhouse, ViiV Healthcare CEO

Un­der pres­sure from ad­vo­cates, Vi­iV strikes a deal to make its long-act­ing HIV in­jectable more ac­ces­si­ble

A week af­ter ad­vo­cates called up­on Vi­iV Health­care to low­er the price of its long-act­ing HIV in­jectable Apre­tude, the com­pa­ny has struck a deal to make the drug more ac­ces­si­ble in low- and mid­dle-in­come coun­tries.

Vi­iV and the Med­i­cines Patent Pool (MPP) signed a vol­un­tary li­cens­ing agree­ment that will al­low gener­ic man­u­fac­tur­ers in 90 coun­tries to de­vel­op, man­u­fac­ture and sup­ply their own ver­sions of Apre­tude, “sub­ject to re­quired reg­u­la­to­ry ap­provals be­ing ob­tained,” the part­ners an­nounced on Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.